Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.46 |
| ▸ | IGF1R | P08069 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414199 | 0.88 | NEK1 (0.51) | AXLAAK1RIPK1IGF1RBRD4 | |
| SCHEMBL416743 | 0.86 | MAP2K1 (0.48) | NPC1TSHRRAB9ASMN1; SMN2BDKRB1 | |
| SCHEMBL415532 | 0.85 | PYGL (0.47) | AAK1RIPK1IGF1RMAPK1BDKRB1 | |
| SCHEMBL20090438 | 0.77 | RIPK1 (0.40) | AAK1RIPK1IGF1RNPC1TSHR | |
| SCHEMBL12769509 | 0.77 | AXL (0.52) | AXLSMN1; SMN2CNR1 | |
| SCHEMBL412504 | 0.77 | CDK8 (0.54) | AAK1RIPK1IGF1RTSHRBRD4 | |
| SCHEMBL413734 | 0.74 | TSHR (0.52) | AAK1RIPK1IGF1RNPC1TSHR | |
| SCHEMBL416381 | 0.74 | CDK8 (0.50) | RIPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL416393 | 0.74 | CDK8 (0.51) | AAK1RIPK1IGF1R | |
| SCHEMBL416103 | 0.73 | RIPK1 (0.59) | AXLAAK1RIPK1IGF1RBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885AAK1 335/4885RIPK1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.